Vantia Therapeutics appoints new chief executive
Andrew Crockett wins promotion after 12 months with pharma company
Since joining the Southampton, UK-based emerging pharmaceutical firm in 2009 as vice president of business development, Crockett has made a significant contribution to Vantia’s corporate development. He was previously with US specialist pharma company ZARS Pharma.
Martin Murphy, non-executive chairman of Vantia, said: ‘We are very pleased that Andrew Crockett has accepted the position as ceo. Vantia has made considerable progress over the past two years in advancing its pipeline of novel small molecule drug candidates into Phase II clinical trials. We wish Jim Phillips, the former ceo, well and appreciate his contribution to the team. The management team has created a solid platform for Vantia and we are therefore very pleased that Andrew will continue the great work that has been started.’
Crockett added: ‘We are looking forward to an exciting second half of the year when we expect important clinical data from our Phase IIa efficacy study in dysmenorrhoea and from our Phase IIb study in nocturia.’
Vantia Therapeutics develops novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research’s small molecule r&d, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.
You may also like
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery
New cancer drug delivery system boosts absorption of Paclitaxel
Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Research & Development
3PBIOVIAN and Colombia's National Cancer Institute partner to develop first locally produced oncology biosimilar
The CDMO has signed an agreement with Colombia's Instituto Nacional de Cancerología to develop a biosimilar monoclonal antibody for an oncology indication, with technology transfer planned to enable domestic manufacturing